Richard Greil

Richard Greil publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard Greil sits on this spectrum.

Richard Greil D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard Greil sits on this spectrum.

Research.com Recognitions

• Member of the European Academy of Sciences and Arts
• Member of the European Academy of Sciences and Arts

Overview

Best Publications

• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

  Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  2608
  Citations

• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

  Raimund Jakesz;Walter Jonat;Michael Gnant;Martina Mittlboeck

  1249
  Citations

• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

  Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  752
  Citations

• Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

  Carol Moreno;Richard Greil;Fatih Demirkan;Alessandra Tedeschi

  577
  Citations

• Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

  Hans Theodor Eich;Volker Diehl;Helen Görgen;Thomas Pabst

  525
  Citations

• Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

  M. Gnant;M. Filipits;R. Greil;H. Stoeger

  444
  Citations

• Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

  José Baselga;Patricia Gómez;Richard Greil;Sofia Braga

  424
  Citations

• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

  Vivek Subbiah;Ulrik Lassen;Elena Élez;Antoine Italiano

  402
  Citations

• The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

  P Dubsky;J C Brase;R Jakesz;M Rudas

  395
  Citations

• PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

  Peter Borchmann;Helen Goergen;Carsten Kobe;Andreas Lohri

  380
  Citations

• AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

  Luca Gianni;Gilles H. Romieu;Michail Lichinitser;Sergio V. Serrano

  337
  Citations

• Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

  M. Gnant;B. Mlineritsch;H. Stoeger;G. Luschin-Ebengreuth

  335
  Citations

• T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

  Claudia Zelle-Rieser;Shanmugapriya Thangavadivel;Rainer Biedermann;Andrea Brunner

  320
  Citations

• Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

  Florence Ader;Maude Bouscambert-Duchamp;Maya Hites;Nathan Peiffer-Smadja;Nathan Peiffer-Smadja

  319
  Citations

• Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

  Andreas Tiede;Robert Klamroth;Rüdiger E. Scharf;Ralf U. Trappe

  288
  Citations

• Drug-induced Apoptosis Is Associated with Enhanced Fas (Apo-1/CD95) Ligand Expression but Occurs Independently of Fas (Apo-1/CD95) Signaling in Human T-Acute Lymphatic Leukemia Cells

  Andreas Villunger;Alexander Egle;Marion Kos;Bernd L. Hartmann

  270
  Citations

• Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

  Richard F. Schlenk;Richard F. Schlenk;Daniela Weber;Walter Fiedler;Helmut R. Salih

  265
  Citations

• Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

  Heinz Gisslinger;Christoph Klade;Pencho Georgiev;Dorota Krochmalczyk

  259
  Citations

• The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

  Martin Filipits;Torsten O. Nielsen;Margaretha Rudas;Richard Greil

  250
  Citations

• Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

  Georg Pfeiler;Robert Königsberg;Christian Fesl;Brigitte Mlineritsch

  248
  Citations